Pre-made Durvalumab benchmark antibody ( Whole mAb, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Durvalumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-159-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Durvalumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
INN Name	Durvalumab
Target	PD-L1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5xj4:HL/5x8m:BC
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine
Conditions Approved	Non-small cell lung cancer;Urogenital cancer;Small cell lung cancer
Conditions Active	Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer
Conditions Discontinued	CNS cancer;Lymphoproliferative disorders;Thyroid cancer
Development Tech	na